Actionable news
All posts from Actionable news
Actionable news in ACOR: Acorda Therapeutics, Inc.,

Goldman On Biotech: Buy Sage, Sell Acorda, Neutral On Dimension

Trade with confidence. Are you a professional trader? Be the first to get the alert with Benzinga Pro's real-time newsfeed and audio squawk and never miss an opportunity again.
Don't miss the chance to try it FREE today.

Goldman Sachs’ Salveen Richter maintained a Neutral coverage view on the small- to mid-cap biotech segment, while advocating selectivity “based on positive catalysts, EPS execution & M&A optionality.”

Biotech stocks on average have underperformed year-to-date, with the NBI down 24 percent versus a 0.54 percent gain in the S&P. The pressure has resulted from several factors, including macro concerns, drug pricing pressure caused by political headlines and sector-specific events, such as mixed EPS, limited positive news flow and no large M&A, analyst Salveen Richter said.

Sage: Catalysts Provide Upside

Richter initiated coverage of SAGE Therapeutics Inc SAGE with a Buy rating and a price target of $63. The company is a key player in acute central nervous system [CNS] disorders and has a portfolio of...